

Ferenc B Sallo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9246704/publications.pdf>

Version: 2024-02-01

16
papers

624
citations

759233

12
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

622
citing authors

#	ARTICLE	IF	CITATIONS
1	En face OCT Imaging of the IS/OS Junction Line in Type 2 Idiopathic Macular Telangiectasia. , 2012, 53, 6145.		98
2	Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results From a Phase 1 Safety Trial. American Journal of Ophthalmology, 2015, 159, 659-666.e1.	3.3	72
3	The IS/OS Junction Layer in the Natural History of Type 2 Idiopathic Macular Telangiectasia. , 2012, 53, 7889.		70
4	Cone photoreceptor definition on adaptive optics retinal imaging. British Journal of Ophthalmology, 2014, 98, 1073-1079.	3.9	55
5	Retinal Crystals in Type 2 Idiopathic Macular Telangiectasia. Ophthalmology, 2011, 118, 2461-2467.	5.2	54
6	CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2018, 38, S8-S13.	1.7	51
7	MULTIMODAL IMAGING IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. Retina, 2015, 35, 742-749.	1.7	35
8	Bruch's membrane changes in transgenic mice overexpressing the human biglycan and apolipoprotein b-100 genes. Experimental Eye Research, 2009, 89, 178-186.	2.6	28
9	CHARACTERISTICS OF PIGMENTED LESIONS IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. Retina, 2018, 38, S43-S50.	1.7	28
10	ABNORMAL RETINAL REFLECTIVITY TO SHORT-WAVELENGTH LIGHT IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. Retina, 2018, 38, S79-S88.	1.7	26
11	CORRELATION OF STRUCTURAL AND FUNCTIONAL OUTCOME MEASURES IN A PHASE ONE TRIAL OF CILIARY NEUROTROPHIC FACTOR IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. Retina, 2018, 38, S27-S32.	1.7	23
12	Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2. Acta Ophthalmologica, 2019, 97, e998-e1005.	1.1	22
13	Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice. Frontiers in Pharmacology, 2021, 12, 720345.	3.5	18
14	ELECTROPHYSIOLOGICAL CHARACTERIZATION OF MACULAR TELANGIECTASIA TYPE 2 AND STRUCTURE-FUNCTION CORRELATION. Retina, 2018, 38, S33-S42.	1.7	15
15	Genetic disruption of serine biosynthesis is a key driver of macular telangiectasia type 2 aetiology and progression. Genome Medicine, 2021, 13, 39.	8.2	15
16	The International Classification System and the Progression of Age-Related Macular Degeneration. Current Eye Research, 2009, 34, 238-240.	1.5	14